Testing the Effects of Removing Gabapentin from Standard Pre-Surgical Orders on Pain Control in Patients Undergoing Mastectomy, GABS-DART Trial

This clinical trial evaluates whether removing gabapentin from the pre-surgical order set of patients undergoing mastectomy affects pain control after surgery. Gabapentin is commonly used to reduce opioid consumption and manage neuropathic pain, but evidence of its effectiveness in surgical settings is limited, and its use is controversial. Some studies show that using gabapentin around the time of surgery may reduce the amount of opioid pain medicines patients need after surgery, but it also has the potential for increased side effects. The standard set of orders added to a patient's medical record before mastectomy includes a default selection of gabapentin use. This study evaluates whether altering these orders to remove the default selection of gabapentin results in changes to pain outcomes in patients undergoing mastectomy.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07308717.

Trial PhaseNo phase specified

Trial Typesupportive care

Lead OrganizationMemorial Sloan Kettering Cancer Center

Principal InvestigatorJames Flory

• Primary ID25-183
• Secondary IDsNCI-2025-09674
• ClinicalTrials.gov IDNCT07308717